|
1
|
Weir HK, Thun MJ, Hankey BF, et al: Annual
report to the nation on the status of cancer, 1975–2000, featuring
the uses of surveillance data for cancer prevention and control. J
Natl Cancer Inst. 95:1276–1299. 2003.
|
|
2
|
Gridelli C, Perrone F and Monfardini S:
Lung cancer in the elderly. Eur J Cancer. 33:2313–2314. 1997.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Bunn PA Jr and Lilenbaum R: Chemotherapy
for elderly patients with advanced non-small cell lung cancer. J
Natl Cancer Inst. 95:341–343. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Alam N, Shepherd FA, Winton T, et al:
Compliance with post-operative adjuvant chemotherapy in non-small
cell lung cancer: an analysis of National Cancer Institute of
Canada and intergroup trial JBR10 and a review of the literature.
Lung Cancer. 47:385–394. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Balducci L: Geriatric oncology: challenges
for the new century. Eur J Cancer. 36:1741–1754. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Balducci L: Geriatric oncology. Crit Rev
Oncol Hematol. 46:211–220. 2003. View Article : Google Scholar
|
|
7
|
Asmis TR, Ding K, Seymour L, et al;
National Cancer Institute of Canada Clinical Trials Group. Age and
comorbidity as independent prognostic factors in the treatment of
non-small cell lung cancer: a review of National Cancer Institute
of Canada Clinical Trials Group trials. J Clin Oncol. 26:54–59.
2008. View Article : Google Scholar
|
|
8
|
Gridelli C, Perrone F, Gallo C, et al:
Chemotherapy for elderly patients with advanced non-small cell lung
cancer: the Multicenter Italian Lung Cancer in the Elderly Study
(MILES) phase III randomized trial. J Natl Cancer Inst. 95:362–372.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Boukovinas I, Souglakos J, Hatzidaki D, et
al: Docetaxel plus gemcitabine as front-line chemotherapy in
elderly patients with lung adenocarcinomas: a multicenter phase II
study. Lung Cancer. 63:77–82. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Gridelli C, De Maio E, Barbera S, et al:
The MILES-2G phase 2 study of single-agent gemcitabine with
prolonged constant infusion in advanced non-small cell lung cancer
elderly patients. Lung Cancer. 61:67–72. 2008. View Article : Google Scholar
|
|
11
|
Pallis AG, Polyzos A, Boukovinas I, et al:
Pooled analysis of elderly patients with non-small cell lung cancer
treated with front line docetaxel/gemcitabine regimen: the Hellenic
Oncology Research Group experience. J Thorac Oncol. 3:505–510.
2008. View Article : Google Scholar
|
|
12
|
Jackman DM, Yeap BY, Lindeman NI, et al:
Phase II clinical trial of chemotherapy-naive patients > or = 70
years of age treated with erlotinib for advanced non-small cell
lung cancer. J Clin Oncol. 25:760–766. 2007.
|
|
13
|
Shepherd FA, Rodrigues Pereira J, Ciuleanu
T, et al; National Cancer Institute of Canada Clinical Trials
Group. Erlotinib in previously treated non-small-cell lung cancer.
N Engl J Med. 353:123–132. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Reck M, van Zandwijk N, Gridelli C, et al:
Erlotinib in advanced non-small cell lung cancer: efficacy and
safety findings of the global phase IV Tarceva Lung Cancer Survival
Treatment study. J Thorac Oncol. 5:1616–1622. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Therasse P, Arbuck SG, Eisenhauer EA, et
al: New guidelines to evaluate the response to treatment in solid
tumors. J Natl Cancer Inst. 92:205–216. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
The Elderly Lung Cancer Vinorelbine
Italian Study Group. Effects of vinorelbine on quality of life and
survival of elderly patients with advanced non-small-cell lung
cancer. J Natl Cancer Inst. 91:66–72. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Kudoh S, Takeda K, Nakagawa K, et al:
Phase III study of docetaxel compared with vinorelbine in elderly
patients with advanced non-small-cell lung cancer: results of the
West Japan Thoracic Oncology Group Trial (WJTOG 9904). J Clin
Oncol. 24:3657–3663. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Frasci G, Lorusso V, Panza N, et al:
Gemcitabine plus vinorelbine yields better survival outcome than
vinorelbine alone in elderly patients with advanced non-small cell
lung cancer. A Southern Italy Cooperative Oncology Group (SICOG)
phase III trial. Lung Cancer. 34:S65–S69. 2001. View Article : Google Scholar
|
|
19
|
Hainsworth JD, Spigel DR, Farley C, et al:
Weekly docetaxel versus docetaxel/gemcitabine in the treatment of
elderly or poor performance status patients with advanced non small
cell lung cancer: a randomized phase 3 trial of the Minnie Pearl
Cancer Research Network. Cancer. 110:2027–2034. 2007. View Article : Google Scholar
|
|
20
|
Ramalingam SS, Dahlberg SE, Langer CJ, et
al: Outcomes for elderly, advanced-stage non small-cell lung cancer
patients treated with bevacizumab in combination with carboplatin
and paclitaxel: analysis of Eastern Cooperative Oncology Group
Trial 4599. J Clin Oncol. 26:60–65. 2008. View Article : Google Scholar
|
|
21
|
Wheatley-Price P, Ding K, Seymour L, et
al: Erlotinib for advanced non-small cell lung cancer in the
elderly: an analysis of the National Cancer Institute of Canada
Clinical Trials Group Study BR. 21. J Clin Oncol. 26:2350–2357.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Wacker B, Nagrani T, Weinberg J, et al:
Correlation between development of rash and efficacy in patients
treated with the epidermal growth factor receptor tyrosine kinase
inhibitor erlotinib in two large phase III studies. Clin Cancer
Res. 13:3913–3921. 2007. View Article : Google Scholar
|
|
23
|
Lee S, Rudd R, Khan I, et al: TOPICAL:
randomized phase III trial of erlotinib compared with placebo in
chemotherapy-naïve patients with advanced non-small cell lung
cancer (NSCLC) and unsuitable for first-line chemotherapy. J Clin
Oncol. 28(Suppl 15): 75042010.
|
